Thetis Expands HEALER Technology Patent Estate

SOUTHPORT, Connecticut, June 20, 2014—Thetis Pharmaceuticals LLC (“Thetis”), an emerging biopharmaceutical company focused on cardio-metabolic diseases, announced today the filing of two patent applications that broaden its foundation for identification and selection of multiple new therapeutic compounds for development. The patents expand the company’s HEALER℠ Technology (High Efficiency Amino Lipid Enabled Release) with proprietary amino-lipid based drugs that deliver the free acid of eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), the principal bio-active agents in omega-3 polyunsaturated fatty acids. Unlike Lovaza, Vascepa and Epanova, which are the only omega-3 prescription drugs approved in the United States, the new molecular entities developed by Thetis are solid, stable materials which can be administered orally or parenterally to deliver high plasma levels of the free fatty acids, of EPA or DHA. In addition, the unique scaffolds created with the HEALER℠ Technology can deliver other, non-omega-3 active agents, further amplifying Thetis’ ability to develop differentiated candidates outside the traditional omega-3 arena which has been limited to severe hypertriglyceridemia.